FDA Import Refusal BUU-1821955-6/10002/1 — Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
The FDA refused shipment BUU-1821955-6/10002/1 from Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (China) on July 2, 2026. The refused product falls under Drugs and Biologics — ORFORGLIPRON (ANTI-DIABETIC). Cited charge: 27 This firm has 1 other import refusal on record.
Refusal Details
- Date
- July 2, 2026
- Country
- China
- Product Category
- Drugs and Biologics
- Product Code
- 61PAY77 ORFORGLIPRON (ANTI-DIABETIC)
- Charges
- 27